2017 Fiscal Year Final Research Report
New therapeutic strategy for NASH-related HCC targeting lipid metabolism
| Project/Area Number |
15K19313
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | NASH / 肝細胞癌 / メタボリックリプログラミング / CPT2 / アシルカルニチン |
|---|
| Outline of Final Research Achievements |
We conducted untargeted metabolomics profiling using obesity-driven HCC mouse models, and found suppression of fatty acid β-oxidation (FAO) and subsequent extensive accumulation of acylcarnitine species in HCC tissues, which was caused by downregulation of CPT2, a key enzyme of FAO. CPT2 downregulation enabled HCC cells to escape lipotoxicity by inhibiting Src-mediated JNK activation, and accumulated acylcarnitine, specifically oleoylcarnitine, enhanced carcinogenesis by conferring stem cell properties to HCC through STAT3 activation. A high-fat diet and carnitine supplementation synergistically promoted HCC development with acylcarnitine accumulation in mice. Intriguingly, in obesity-driven HCC, glucose was utilized for oxidative phosphorylation to compensate suppressed FAO, unlike the Warburg effect. NASH-HCC patients also revealed CPT2-mediated metabolic reprogramming. Increased serum acylcarnitine was a potential biomarker of NASH-HCC.
|
| Free Research Field |
消化器病
|
